SFPM(SZ:002737)2021-04-20 16:00Financial Performance - The company's operating revenue for 2020 was ¥3,461,888,347.20, a decrease of 20.81% compared to ¥4,371,413,641.89 in 2019[27]. - The net profit attributable to shareholders of the listed company was ¥584,454,186.65, an increase of 3.37% from ¥565,422,018.73 in 2019[27]. - The net profit after deducting non-recurring gains and losses was ¥474,091,995.04, down 5.31% from ¥500,681,508.67 in 2019[27]. - The net cash flow from operating activities increased by 19.21% to ¥1,169,867,011.53 from ¥981,327,677.71 in 2019[27]. - The basic earnings per share for 2020 was ¥1.00, up 3.09% from ¥0.97 in 2019[27]. - Total assets at the end of 2020 were ¥5,113,343,143.57, a decrease of 3.69% from ¥5,309,290,285.34 at the end of 2019[27]. - The net assets attributable to shareholders of the listed company were ¥3,180,232,064.90, down 1.36% from ¥3,224,119,367.21 at the end of 2019[27]. - The company achieved total revenue of CNY 346,188.83 million in 2020, a decrease of 20.81% compared to the previous year[54]. - Operating profit was CNY 76,662.19 million, an increase of 0.82% year-on-year[54]. - Net profit attributable to shareholders was CNY 58,445.42 million, reflecting a growth of 3.37% compared to the previous year[54]. Dividend Distribution - The company reported a cash dividend of 3.5 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[7]. - The company distributed a cash dividend of 10 yuan (including tax) for every 10 shares for the 2019 fiscal year, totaling 58.4 million yuan[147]. - For the 2020 fiscal year, the company plans to distribute a cash dividend of 3.5 yuan (including tax) for every 10 shares, with a total cash dividend amount of 201.9 million yuan[149]. - The total cash dividend for 2020, including other methods, amounts to 285.5 million yuan, representing 48.84% of the distributable profit[154]. - The cash dividend for 2019 was 582.4 million yuan, which exceeded the net profit attributable to ordinary shareholders by 103.01%[153]. - The company has established a three-year dividend return plan (2020-2022) to ensure the continuity and stability of its dividend distribution policy[147]. - The cash dividend policy is compliant with the company's articles of association and has been approved by the shareholders' meeting[148]. - The company aims to protect the interests of shareholders, especially small and medium-sized investors, through its dividend distribution plan[147]. Market Strategy and Expansion - The company aims to enhance its market expansion and product development strategies in the upcoming fiscal year[7]. - The company is focusing on expanding its gynecological and chronic disease medication categories to complement its pediatric offerings[41]. - The company is actively engaged in drug research and development, highlighting its commitment to innovation in the pharmaceutical sector[133]. - The company is focused on the overseas sales of its products, indicating a strategic push for international market expansion[133]. - Market expansion plans include entering two new international markets by Q3 2021, projected to increase market share by 5%[132]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $30 million allocated for potential deals[132]. - The company is exploring potential market expansion opportunities to drive growth[140]. Risk Management - The company faced risks including industry policy changes, raw material price fluctuations, and uncertainties due to the pandemic[7]. - The company emphasizes the importance of risk awareness among investors regarding future development plans[7]. - Strategic reserves for core raw materials will be established to mitigate procurement risks associated with price volatility[124]. - The company will closely monitor industry policy dynamics and adjust its operational strategies accordingly to enhance core competitiveness[124]. - The company is actively monitoring the impact of the COVID-19 pandemic on product sales and overall performance[136]. Research and Development - The company has initiated the development of over 20 new chemical drugs, with more than 10 products currently in the research phase[60]. - The company is focusing on developing new products, including Ibuprofen suspension and liver protection tablets, with ongoing clinical trials[79]. - The company has implemented a five-pronged channel management strategy, enhancing coverage in hospitals and retail markets across all provinces except Tibet[55]. - The company has improved its production quality control, achieving a reduction in manufacturing costs while maintaining safety standards[56]. - The company is committed to enhancing the safety and efficacy of its children's medications, ensuring they meet high-quality standards[47]. Corporate Governance - The company’s legal representative is Guan Yuxiu, who oversees the strategic direction and governance[20]. - The company is preparing for its shareholder meeting, which will address dividend distribution and other key matters[133]. - The company is monitoring the shareholding structure and stock price trends closely, reflecting its attention to market dynamics[133]. - The company confirmed that it has fulfilled its commitments to minority shareholders in a timely manner[166]. - The actual controller of the company, Guan Yanbin, was sentenced to 11 years in prison for intentional homicide, but this incident did not affect the company's normal operations[177][180]. Financial Management - The company has established a dedicated management system for the raised funds to ensure their effective use and safeguard investor interests[101]. - The company has not reported any overdue commitments that remain unfulfilled[164]. - The company has diversified its investments across various asset classes, including money market assets and bonds[200]. - The management strategy focuses on maximizing returns while maintaining liquidity and safety in cash asset management[197]. - The company has utilized idle self-owned funds for all entrusted financial products, ensuring liquidity[197]. Operational Performance - The company reported a significant increase in revenue, with a year-over-year growth of 25% in Q4 2020[132]. - User data showed a 15% increase in active users, reaching a total of 5 million by the end of the fiscal year[132]. - The company provided guidance for the next quarter, expecting revenue growth of 20% compared to the previous quarter[132]. - The impact of the pandemic on production was minimal, with production capacity maintained at 90% throughout the year[132]. - Customer satisfaction ratings improved by 12%, reflecting the effectiveness of recent service enhancements[132].